What to know
- Nirsevimab is a monoclonal antibody that prevents severe RSV disease and is recommended for infants and some young children.
- Pregnant women should get a single dose of the maternal RSV vaccine (Pfizer’s Abrysvo) during weeks 32 through 36 of pregnancy to protect their baby from severe RSV disease.
- CDC recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 50-74 at increased risk of severe RSV. Adults who have already received one dose (including last year) should not receive another dose at this time.
RSV vaccine guidance index
Click on the pages below to learn more about RSV vaccine and immunizations for each population:
Immunization guidance for healthcare providers for the use of nirsevimab
Clinical guidance for the use of the RSV maternal vaccine (Pfizer's Abrysvo)
Vaccine guidance for healthcare providers for the use of RSV vaccines for adults